Cross-Hypothesis Convergence Patterns

1 The Dopamine Convergence Node

Certainty: 0.35. Convergence of multiple hypotheses on dopamine dysfunction is a structural feature of the model space, not an empirical finding. Each contributing hypothesis has its own evidence base.

Multiple hypotheses converge on basal ganglia/PFC dopamine dysfunction:

  • TRPM3 channelopathy: TRPM3 calcium β†’ VMAT2 vesicular loading β†’ dopamine packaging impaired.
  • Microglial neuroinflammation: Cytokines β†’ BH4 depletion β†’ tyrosine hydroxylase failure β†’ reduced dopamine synthesis.
  • GPCR autoantibodies: Ξ²2-AR AAb on LC β†’ NE deficiency β†’ reduced VTA dopamine neuron activation.
  • Kynurenine pathway: Quinolinic acid β†’ NMDA excitotoxicity in striatum β†’ D2 receptor internalization.
  • Central NE deficiency: DBH ATP-dependence β†’ NE synthesis failure spares DA (Central Catecholamine Deficiency in ME/CFS β€” Selectively Noradrenergic), but chronic NE deficiency β†’ compensatory DA overdrive β†’ D2 desensitization.
  • Gerlier Pathway 2: Sympathetic chain compression β†’ NE overdrive β†’ DBH overactivity β†’ dopamine pool depletion.

THE DIAGNOSTIC PROBE: Aripiprazole tells you dopamine IS rate-limiting. Distinguishing WHICH upstream driver requires combining with:

  • LDN response β†’ neuroinflammation-driven
  • Immunoadsorption response β†’ autoantibody-driven
  • Memantine response β†’ kynurenine/excitotoxicity-driven
  • Atomoxetine/NRI response β†’ NE deficiency-driven
  • Shoe lift response β†’ Gerlier Pathway 2
ImportantFinding: Aripiprazole + shoe lift response localizes dopamine lesion to Gerlier Pathway 2

If aripiprazole works and ONLY shoe lift works (no LDN, no IA, no memantine): dopamine lesion is specifically from Gerlier Pathway 2.

Certainty
Low
Level of action
Partial root cause

Consequence: Aripiprazole is the convergence probe β€” it tells you dopamine dysfunction is rate-limiting but not WHY. Probe COMBINATIONS are diagnostic. Origin: mechanistic-pathway-tracing.

2 The Noradrenergic Selectivity Node

Certainty: 0.40. Selective noradrenergic defect (CSF NE↓, DA preserved per Central Catecholamine Deficiency in ME/CFS β€” Selectively Noradrenergic) is a replicated finding from NIH deep phenotyping, though single-center and n=16–17.

The selective noradrenergic defect creates a specific test:

ImportantFinding: Atomoxetine should improve fatigue and PEM if NE deficiency is rate-limiting

Atomoxetine (NRI) should improve fatigue and PEM if NE deficiency is rate-limiting.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: Atomoxetine may NOT improve cognitive symptoms if DA system is intact or cognitive bottleneck is glutamatergic

Atomoxetine may NOT improve cognitive symptoms if DA system is intact or cognitive bottleneck is glutamatergic.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: Atomoxetine failure + aripiprazole success β†’ lesion downstream of NE at DBH

If atomoxetine does NOT work BUT aripiprazole works β†’ lesion is downstream of NE: DBH failure produces NE deficiency but spares DA, and DA deficiency is rate-limiting.

Certainty
Low
Level of action
Partial root cause

3 Upstream-Node Convergence on the Noradrenergic Selectivity Node

Certainty: n/a (convergence). Independent upstream mechanisms converge on the same selective norepinephrine deficit. Copper-dependent dopamine-Ξ²-hydroxylase synthesis (Lutsenko et al. 2019) (human proof-of-principle (Senard and Rouet 2006)), BH4 cofactor supply (Rivera et al. 2017), ATP-dependent vesicular release (Rangaraju, Calloway, and Ryan 2014), NET reuptake capacity (Hahn, Robertson, and Blakely 2003), and adrenergic-receptor autoantibody signalling (Hartwig et al. 2020) all feed the same endpoint β€” low central NE with preserved dopamine (Central Catecholamine Deficiency in ME/CFS β€” Selectively Noradrenergic). Downstream, the deficit branches to sleep (Osorio-Forero et al. 2021) and pain (Hayashida and Obata 2019) endpoints.

Because the nodes imply different drugs, the differential-response pattern localises the bottleneck: a droxidopa (DBH-bypass) responder whose atomoxetine (NET) response is null points to a presynaptic synthesis/storage lesion, whereas the reverse points downstream. The trace is maintained at ops/integration-guides/pathway-drug-trace-noradrenergic-full-scope.md.

Consequence: the noradrenergic selectivity node is a convergence point, not a single mechanism β€” so a null response to one noradrenergic drug does not refute the hypothesis, it narrows the node.

4 The Perfusion-Delivery vs. Mitochondrial-Production Node

Distinguishing whether the energy bottleneck is oxygen delivery or mitochondrial utilization:

  • Probes: Pyridostigmine (improves perfusion β†’ delivery), CoQ10/NMN (improves mitochondrial function β†’ production).
ImportantFinding: If pyridostigmine works but CoQ10 does NOT β†’ bottleneck at delivery

If pyridostigmine works but CoQ10 does NOT: Bottleneck is at delivery (Step 1). Mitochondria can produce ATP when they get oxygen.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: If CoQ10 works but pyridostigmine does NOT β†’ bottleneck at mitochondrial production

If CoQ10 works but pyridostigmine does NOT: Bottleneck is at mitochondrial production.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: If both work β†’ both delivery and production impaired

If both work: Both delivery and production impaired.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: If neither works β†’ bottleneck at ATP utilization

If neither works: Bottleneck at ATP utilization (ANT export, creatine phosphate shuttle, or triage allocation).

Certainty
Low
Level of action
Partial root cause

5 The Mechanical-vs-Biochemical Dichotomy (Gerlier vs. Autoimmune/Metabolic)

The diagnostic probes that distinguish mechanical from biochemical drivers:

ImportantFinding: Shoe lift works β†’ mechanical driver

Shoe lift: If it works β†’ mechanical driver. HIGH SPECIFICITY for Gerlier cascade.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: Cervical collar works β†’ CCI or functional CCI

Cervical collar: If it works β†’ CCI or functional CCI (Pathway 4).

Certainty
Low
Level of action
Partial root cause
ImportantFinding: Immunoadsorption / BC007 works β†’ autoimmune driver

Immunoadsorption / BC007: If it works β†’ autoimmune driver.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: LDN works β†’ neuroinflammation or TRPM3

LDN: If it works β†’ neuroinflammation or TRPM3. Not specific alone.

Certainty
Low
Level of action
Partial root cause
ImportantFinding: Aripiprazole works for BOTH Gerlier and biochemical β€” must combine with other probes

Aripiprazole (the convergence probe): Works for BOTH Gerlier and biochemical dopamine dysfunction β€” does not distinguish. Must be combined with above probes.

Certainty
Low
Level of action
Partial root cause

References

Hahn, Maureen K., David Robertson, and Randy D. Blakely. 2003. β€œA Mutation in the Human Norepinephrine Transporter Gene (SLC6A2) Associated with Orthostatic Intolerance Disrupts Surface Expression of Mutant and Wild-Type Transporters.” The Journal of Neuroscience 23 (11): 4470–78. https://doi.org/10.1523/JNEUROSCI.23-11-04470.2003.
Hartwig, J., F. Sotzny, S. Bauer, H. Heidecke, G. Riemekasten, D. Dragun, C. Meisel, C. Dames, P. Grabowski, and C. Scheibenbogen. 2020. β€œIgG Stimulated \(\beta\)2 Adrenergic Receptor Activation Is Attenuated in Patients with ME/CFS.” Brain, Behavior, & Immunity - Health 3: 100047. https://doi.org/10.1016/j.bbih.2020.100047.
Hayashida, Ken-ichiro, and Hideaki Obata. 2019. β€œStrategies to Treat Chronic Pain and Strengthen Impaired Descending Noradrenergic Inhibitory System.” International Journal of Molecular Sciences 20 (4): 822. https://doi.org/10.3390/ijms20040822.
Lutsenko, Svetlana, Clorissa Washington-Hughes, Martina Ralle, and Katharina Schmidt. 2019. β€œCopper and the Brain Noradrenergic System.” Journal of Biological Inorganic Chemistry 24 (8): 1179–88. https://doi.org/10.1007/s00775-019-01737-3.
Osorio-Forero, Alejandro, Romain Cardis, Gil Vantomme, Anita Guillaume-Gentil, Georgia Katsioudi, Christophe Devenoges, Laura M. J. Fernandez, and Anita LΓΌthi. 2021. β€œNoradrenergic Circuit Control of Non-REM Sleep Substates.” Current Biology 31 (22): 5009–5023.e7. https://doi.org/10.1016/j.cub.2021.09.041.
Rangaraju, Vidhya, Nathaniel Calloway, and Timothy A. Ryan. 2014. β€œActivity-Driven Local ATP Synthesis Is Required for Synaptic Function.” Cell 156 (4): 825–35. https://doi.org/10.1016/j.cell.2013.12.042.
Rivera, Jose Carlos, Boutheyna Noueihed, Ankush Madaan, Isabelle Lahaie, Jie Pan, Jaques Belik, and Sylvain Chemtob. 2017. β€œTetrahydrobiopterin (BH4) Deficiency Is Associated with Augmented Inflammation and Microvascular Degeneration in the Retina.” Journal of Neuroinflammation 14 (1): 181. https://doi.org/10.1186/s12974-017-0955-x.
Senard, Jean-Michel, and Philippe Rouet. 2006. β€œDopamine Beta-Hydroxylase Deficiency.” Orphanet Journal of Rare Diseases 1: 7. https://doi.org/10.1186/1750-1172-1-7.